Gilead's Truvada Sales on Light Side
Updated from 4:34 p.m. EST
While Gilead Sciences (GILD) saw its fourth-quarter revenue jump, the company reported mixed sales results for some of its major drugs, sending its shares lower in after-hours trading.
According to Gilead, fourth-quarter revenue rose 65% from a year ago, and product sales climbed for the ninth straight quarter thanks to its HIV drug Truvada and hepatitis B treatment Hepsera.
Sales of Truvada, the company's biggest HIV drug, rose 18% from the third quarter to $191.1 million, but analysts were disappointed. Forecasters expected Truvada sales to reach $197 million. The drug, which launched in the U.S. in the third quarter of 2004 and in certain European countries in 2005, accounted for 50% of Gilead's total HIV product sales for the fourth quarter.
As patients switched over to Truvada from Viread, sales of the older HIV drug fell 8% from the 2004 fourth quarter to $182.4 million. Sales of another HIV drug, Emtriva, slid 15% from a year ago to $11.2 million, but the decline wasn't as bad as the expected drop to $9.3 million. Sales of AmBisome, a treatment for severe fungal infections, and Hepsera were stronger than anticipated. AmBisome brought in $55.6 million in sales for the fourth quarter, up 1%, while revenue from Hepsera totaled $51.2 million, a 43% increase. Overall, product sales totaled $493.4 million. The company's HIV product line had sales of $384.8 million in the fourth quarter, a 47% increase from the same period in 2004, but slightly lower than the consensus projection of $389.8 million. All told, the Foster City, Calif., biopharmaceutical company posted revenue of $609.3 million for the quarter, up from $369.6 million in the same period a year ago. Gilead earned $281.6 million, or 59 cents a share, for the last three months of the fiscal year, more than double the $110.2 million and 24 cents a share last year. Excluding a tax benefit realized from the repatriation of foreign earnings, Gilead would have earned $256.5 million, or 54 cents a share, in the most recent quarter, the company said Monday.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
